Global /Sweden /Healthcare /Drug Manufacturers - General /ERMA

Enorama Pharma AB (publ)

ERMA

• STO: ERMA • Delayed

0.2800SEK 0%

0.0299 USD

As of 6 June 2026, Enorama Pharma AB (publ) has a market cap of $2.23M USD, ranking #46948 globally and #809 in Sweden. It ranks #4156 in the Healthcare sector, and #1316 in the Drug Manufacturers - General industry.

Global Rank

46948

Country Rank

809

Sector Rank

4156

Industry Rank

1316

Key Stats

Market Cap

$2.23MUSD

20.88M SEK

Enterprise Value

$1.9MUSD

17.85M SEK

Revenue (TTM)

$292.22KUSD

2.74M SEK

EBITDA (TTM)

-$6.65MUSD

-62.36M SEK

Net Income (TTM)

-$8.02MUSD

-75.14M SEK

PS Ratio

7.6

PB Ratio

-0.9

Company Profile

Country (HQ)

Sweden

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Bengt Jönsson open_in_new

Employees

Founded

2006

Website

enorama.se open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-9.7%	-24%	-82%	-90%	-85%	-91%	-94%	-99%

News

Markets

Exchange	Ticker	Price	Quotes
Nasdaq Stockholm (STO) MIC: XSTO PRIMARY	ERMA Enorama Pharma AB ISIN: SE0008216329 Shares Out.: Shares Outstanding: 74.589M¹ Shares Float: 74.524M² TV: TradingView: OMXSTO: ERMA SA: Stock Analysis: STO: ERMA YF: Yahoo Finance: ERMA.ST GF: Google Finance: STO: ERMA BA: Barron's: ERMA MS: Morningstar: XSTO: ERMA	0.2800 SEK	TV: TradingView: OMXSTO: ERMA SA: Stock Analysis: STO: ERMA YF: Yahoo Finance: ERMA.ST GF: Google Finance: STO: ERMA BA: Barron's: ERMA MS: Morningstar: XSTO: ERMA

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Enorama Pharma AB (publ)

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.

Similar Companies

Industry: Drug Manufacturers - General (Sweden)

Name	Market Cap (USD) diff.	PE	Country
Swedish Orphan Biovitrum AB (publ) STO: SOBI	$14.88B 139.44B SEK 668K%	152.8	Sweden
Camurus AB (publ) STO: CAMX	$3.35B 31.37B SEK 150K%	42.8	Sweden
BioArctic AB (publ) STO: BIOA-B	$2.93B 27.5B SEK 132K%	26.9	Sweden
Swedencare AB (publ) STO: SECARE	$451.91M 4.24B SEK 20K%	85.9	Sweden
Vicore Pharma Holding AB (publ) STO: VICO	$300.96M 2.82B SEK 13K%	-	Sweden
Hansa Biopharma AB (publ) STO: HNSA	$294.01M 2.76B SEK 13K%	-	Sweden

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 34M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 25M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 16M%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 15M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 13M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 12M%	20.5	Switzerland

chevron_leftBack